Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cadus Pharmaceutical Corp. (KDUS) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (640)	11/19/2001 2:03:02 AM
From: scaram(o)uche	Respond to of 1833

pointer from Peter........ Thursday November 15, 6:59 am Eastern Time Press Release SOURCE: HMSR Inc. HMSR Inc. to Merge With Point Therapeutics, Inc. MARLBOROUGH, Mass., Nov. 15 /PRNewswire/ -- HMSR Inc. (OTC Bulletin: HMSR) announced today that it has signed a definitive agreement to merge with Point Therapeutics, Inc. Following the merger, Point Therapeutics, Inc. will become a wholly-owned subsidiary of HMSR, which will remain a public company. Under the terms of the agreement, each outstanding share of Point Therapeutics' common stock will be converted into the right to receive 37.377 shares of the common stock of HMSR. As a result of the merger, the respective ownership of HMSR's current stockholders and Point Therapeutics' current stockholders in HMSR is anticipated to be approximately 23% and 77%, respectively, subject to downward adjustment for HMSR to the extent HMSR's cash and cash equivalent balances at closing are less than $16.5 million (as of September 30, 2001, HMSR's cash and cash equivalent balances totaled approximately $16.2 million). The transaction is expected to close in the first quarter of 2002, and is subject to approval of each of HMSR's and Point Therapeutics' stockholders and other customary conditions. HMSR Inc., formerly named HemaSure Inc., sold substantially all of its non-cash assets, including its name, to Whatman plc on May 29, 2001. Point Therapeutics is developing novel therapeutics for hematopoietic disorders and cancer treatments. The company's lead compound, PT-100, is an orally available, novel small molecule that is intended to stimulate the growth of multilineage hematopoietic cells. PT-100 is currently being evaluated in a Phase I/II clinical trial intended to investigate its efficacy and safety in the treatment of neutropenia in cancer patients undergoing chemotherapy. Jack McGuire, Director of HMSR Inc. commented: ``Today's announcement marks the end of an extensive and careful review of alternatives by HMSR's Board of Directors, the goal of which was to maximize stockholder value. We believe Point Therapeutics' novel technology and products represent a great opportunity for accomplishing our objective.'' A registration statement relating to the HMSR securities to be issued in connection with the merger will be filed with the Securities and Exchange Commission and has not become effective. The HMSR securities to be issued in connection with the merger may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there by any sale of these securities in any State in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State. Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company's Securities and Exchange Commission filings under ``Risk Factors,'' including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks). For information, including, without limitation, a written prospectus meeting the requirements of Section 10 of the Securities Act when it is available, please contact HMSR Inc. at (508) 357-7740. SOURCE: HMSR Inc.

To: scaram(o)uche who wrote (640)	11/19/2001 3:16:52 PM
From: BulbaMan	Respond to of 1833

"Thanks, BM. did you consider that you might be addressed as such when you chose your handle?....... :-)" Rick: Perhaps unconsciously as here's a typical morning conversation with my dad. Me: How are you doing, dad? Him: It's my lucky day. Me: How come? Him: I already had a BM.

To: scaram(o)uche who wrote (640)	11/20/2001 12:11:46 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 1833

Tuesday November 20, 12:00 pm Eastern Time Press Release SOURCE: OSI Pharmaceuticals, Inc. OSI Pharmaceuticals to Host Conference Call and Webcast From the Company's First Annual Research Day UNIONDALE, N.Y.--(BW HealthWire)--Nov. 20, 2001--OSI Pharmaceuticals, Inc. (Nasdaq:OSIP - news) today announced that it will host a conference call and live webcast on Monday, November 26, at 12:00 p.m. EST from the Company's First Annual Research Day. The webcast will be hosted by Colin Goddard, Ph.D., Chairman and Chief Executive Officer of OSI Pharmaceuticals. OSI's management team is expected to discuss the Company's research and development programs and capabilities, including OSI's leading anti-cancer compound Tarceva(TM) (OSI-774). To access the event by conference call, please dial 800/997-8642 for domestic participants or 973/694-6836 for international participants. To view the event via webcast, please connect to the Company's website at osip.com. In addition, a replay of the presentation will be available from the same website for at least a week following the live presentation. OSI Pharmaceuticals is a research driven biotechnology company primarily focused on the discovery, development and commercialization of innovative products for the treatment of cancer and diabetes, and for selected opportunities arising from the Company's extensive research and development programs. OSI utilizes a comprehensive array of drug discovery and development technologies to target specific genes involved in human disease with novel small molecule drugs. The Company's most advanced drug candidate Tarceva(TM), a small molecule inhibitor of the EGFR gene, is currently in Phase III clinical trials for lung and pancreatic cancer. This news release contains forward-looking statements. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others, uncertainties related to the identification of lead compounds, the successful pre-clinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in OSI Pharmaceuticals' filings with the Securities and Exchange Commission. Contact: OSI Pharmaceuticals, Inc. Kathy Galante, 631/962-2000 kgalante@osip.com or Burns McClellan Representing OSI Ethan Denkensohn (investors) Justin Jackson (media) Kathy Jones, Ph.D. (media) 212/213-0006